TrialThoracic cancer2021

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).

Hisashi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.